Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Background and aims: In the FLOW trial (NCT03819153), semaglutide reduced the risk of major kidney and cardiovascular (CV) events and all-cause death. This analysis explored the effect of semaglutide on key kidney outcomes by baseline characteristics.
Materials and methods: Participants were randomized (1:1) to once-weekly subcutaneous semaglutide 1.0 mg or placebo. The primary outcome was a 5-component composite comprising a ≥50% reduction in estimated glomerular filtration rate (eGFR), eGFR <15 mL/min/1.73 m2, initiation of chronic kidney replacement therapy, and death from kidney or CV causes. For this analysis, an exploratory 4-component, kidney-specific composite outcome (excluding CV death) was evaluated. Kidney failure was defined as persistent eGFR <15 mL/min/1.73 m2 or initiation of chronic kidney replacement therapy. Subgroup analyses were performed using a Cox proportional hazards model (with interaction between treatment group and the relevant subgroup as a fixed factor and stratified by baseline use of a sodium-glucose co-transporter 2 inhibitor).
Results: In total, 3533 participants were randomized to semaglutide 1.0 mg (n=1767) or placebo (n=1766). Baseline mean age was 66.6 years, 69.7% were male, and there was an even distribution of participants across Asia (25.8%), Europe (27.3%), North America (24.5%), and other regions (22.4%). Mean HbA1c was 7.8%, and 56.8% of participants had been diagnosed with diabetes for ≥15 years. A considerable proportion of participants were receiving metformin (51.9%) and insulin (61.4%) at baseline.
The benefit of semaglutide on the 4-component kidney-specific composite outcome was consistent across most baseline subgroups including sex (interaction p value [pint]=0.1557), race (pint= 0.4812), HbA1c (pint=0.4941), retinopathy status (pint=0.4927) and diuretic use (pint=0.2503) (Fig). Treatment effect heterogeneity was observed by baseline diabetes duration, with benefit confined to those with diabetes for ≥15 years (pint=0.0106). Similar results were observed for the time to onset of persistent ≥50% eGFR decline, with consistent treatment effects across most baseline subgroups except for diabetes duration (pint=0.0256). No heterogeneity was observed for the effect of semaglutide on kidney failure across any of the baseline subgroups.
Conclusion: In the FLOW trial, the benefit of semaglutide on key kidney outcomes was generally consistent across baseline subgroups, with the exception of diabetes duration < or >15 years which requires further study.
Figure. Subgroup analyses of the 4-component, kidney-specific composite outcome by baseline characteristics.
